Deficient NLRP3 and AIM2 inflammasome function in autoimmune NZB mice

Journal of Immunology

Volumn 195, Issue 3, 2015, Pages 1233-1241

  Sester, David P ^a   Sagulenko, Vitaliya ^a   Thygesen, Sara J ^a   Cridland, Jasmyn A ^a   Loi, Yen Siew ^a   Cridland, Simon O ^a   Masters, Seth L ^b   Genske, Ulrich ^a   Hornung, Veit ^c   Andoniou, Christopher E ^d,e   Sweet, Matthew J ^a   Degli Esposti, Mariapia A ^d,e   Schroder, Kate ^a   Stacey, Katryn J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e LIONS EYE INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABSENT IN MELANOMA 2 INFLAMMASOME; AUTOANTIBODY; CELL PROTEIN; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; P202 PROTEIN; UNCLASSIFIED DRUG; AIM2 PROTEIN, MOUSE; ANTINUCLEAR ANTIBODY; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; DNA BINDING PROTEIN; IFI202B PROTEIN, MOUSE; IL1B PROTEIN, MOUSE; INTERLEUKIN 1BETA CONVERTING ENZYME; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNITY; BINDING SITE; CANDIDIASIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA VIRUS; FEMALE; INNATE IMMUNITY; INTRON; MACROPHAGE; MOUSE; NEW ZEALAND BLACK MOUSE; NLRP3 GENE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA SPLICING; STOP CODON; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE HEMOLYTIC ANEMIA; BIOSYNTHESIS; CANDIDA ALBICANS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GENETICS; IMMUNOLOGY; MICROBIOLOGY; SIGNAL TRANSDUCTION; VIROLOGY;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; ANTIBODIES, ANTINUCLEAR; AUTOIMMUNITY; CANDIDA ALBICANS; CANDIDIASIS; CARRIER PROTEINS; CASPASE 1; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA-BINDING PROTEINS; INFLAMMASOMES; INTERLEUKIN-1BETA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MACROPHAGES; MICE; MICE, INBRED NZB; SIGNAL TRANSDUCTION;

EID: 84937721277     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402859     Document Type: Article

References (70)

1. Schroder, K., and J. Tschopp. 2010. The inflammasomes. Cell 140: 821-832.
2. Sagulenko, V., S. J. Thygesen, D. P. Sester, A. Idris, J. A. Cridland, P. R. Vajjhala, T. L. Roberts, K. Schroder, J. E. Vince, J. M. Hill, et al. 2013. AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. Cell Death Differ. 20: 1149-1160.
3. Cridland, J. A., E. Z. Curley, M. N. Wykes, K. Schroder, M. J. Sweet, T. L. Roberts, M. A. Ragan, K. S. Kassahn, and K. J. Stacey. 2012. The mammalian PYHIN gene family: phylogeny, evolution and expression. BMC Evol. Biol. 12: 140.
4. Duewell, P., H. Kono, K. J. Rayner, C. M. Sirois, G. Vladimer, F. G. Bauernfeind, G. S. Abela, L. Franchi, G. Nuñez, M. Schnurr, et al. 2010. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464: 1357-1361.
5. Heneka, M. T., M. P. Kummer, A. Stutz, A. Delekate, S. Schwartz, A. Vieira-Saecker, A. Griep, D. Axt, A. Remus, T. C. Tzeng, et al. 2013. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493: 674-678.
6. McGettrick, A. F., and L. A. O'Neill. 2013. NLRP3 and IL-1b in macrophages as critical regulators of metabolic diseases. Diabetes Obes. Metab. 15(Suppl. 3): 19-25.
7. Chen, K. W., and K. Schroder. 2013. Antimicrobial functions of inflammasomes. Curr. Opin. Microbiol. 16: 311-318.
8. Hirota, S. A., J. Ng, A. Lueng, M. Khajah, K. Parhar, Y. Li, V. Lam, M. S. Potentier, K. Ng, M. Bawa, et al. 2011. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm. Bowel Dis. 17: 1359-1372.
9. Zambetti, L. P., and A. Mortellaro. 2014. NLRPs, microbiota, and gut homeostasis: unravelling the connection. J. Pathol. 233: 321-330.
10. Rathinam, V. A., Z. Jiang, S. N. Waggoner, S. Sharma, L. E. Cole, L. Waggoner, S. K. Vanaja, B. G. Monks, S. Ganesan, E. Latz, et al. 2010. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat. Immunol. 11: 395-402.
11. Kayagaki, N., S. Warming, M. Lamkanfi, L. Vande Walle, S. Louie, J. Dong, K. Newton, Y. Qu, J. Liu, S. Heldens, et al. 2011. Non-canonical inflammasome activation targets caspase-11. Nature 479: 117-121.
12. Shi, J., Y. Zhao, Y. Wang, W. Gao, J. Ding, P. Li, L. Hu, and F. Shao. 2014. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514: 187-192.
13. Shaw, P. J., M. F. McDermott, and T. D. Kanneganti. 2011. Inflammasomes and autoimmunity. Trends Mol. Med. 17: 57-64.
14. Kahlenberg, J. M., and M. J. Kaplan. 2014. The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis? Curr. Opin. Rheumatol. 26: 475-481.
15. Szodoray, P., P. Alex, J. G. Brun, M. Centola, and R. Jonsson. 2004. Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scand. J. Immunol. 59: 592-599.
16. Xu, L., T. Zhang, Z. Liu, Q. Li, Z. Xu, and T. Ren. 2012. Critical role of Th17 cells in development of autoimmune hemolytic anemia. Exp. Hematol. 40: 994-1004.e4.
17. Suzuki, H., H. Takemura, and H. Kashiwagi. 1995. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity. Arthritis Rheum. 38: 1055-1059.
18. Willis, R., A. M. Seif, G. McGwin, Jr., L. A. Martinez-Martinez, E. B. González, N. Dang, E. Papalardo, J. Liu, L. M. Vilá, J. D. Reveille, et al. 2012. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 21: 830-835.
19. Yang, Q., C. Yu, Z. Yang, Q. Wei, K. Mu, Y. Zhang, W. Zhao, X.Wang, W. Huai, and L. Han. 2014. Deregulated NLRP3 and NLRP1 inflammasomes and their correlations with disease activity in systemic lupus erythematosus. J. Rheumatol. 41: 444-452.
20. Becker-Merok, A., G. O. Eilertsen, and J. C. Nossent. 2010. Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease. J. Rheumatol. 37: 2039-2045.
21. Sturfelt, G., P. Roux-Lombard, F. A. Wollheim, and J. M. Dayer. 1997. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br. J. Rheumatol. 36: 1283-1289.
22. Dellalibera-Joviliano, R., M. L. Dos Reis, Fde. Q. Cunha, and E. A. Donadi. 2003. Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus. J. Rheumatol. 30: 485-492.
23. Calvani, N., H. B. Richards, M. Tucci, G. Pannarale, and F. Silvestris. 2004. Upregulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clin. Exp. Immunol. 138: 171-178.
24. Tucci, M., C. Quatraro, L. Lombardi, C. Pellegrino, F. Dammacco, and F. Silvestris. 2008. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 58: 251-262.
25. Sugawara, S., A. Uehara, T. Nochi, T. Yamaguchi, H. Ueda, A. Sugiyama, K. Hanzawa, K. Kumagai, H. Okamura, and H. Takada. 2001. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J. Immunol. 167: 6568-6575.
26. Netea, M. G., A. Simon, F. van de Veerdonk, B. J. Kullberg, J. W. Van der Meer, and L. A. Joosten. 2010. IL-1beta processing in host defense: beyond the inflammasomes. PLoS Pathog. 6: e1000661.
27. Pontillo, A., L. Brandao, R. Guimaraes, L. Segat, J. Araujo, and S. Crovella. 2010. Two SNPs in NLRP3 gene are involved in the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil. Autoimmunity 43: 583-589.
28. Villani, A. C., M. Lemire, G. Fortin, E. Louis, M. S. Silverberg, C. Collette, N. Baba, C. Libioulle, J. Belaiche, A. Bitton, et al. 2009. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat. Genet. 41: 71-76.
29. Lewis, G. J., D. C. Massey, H. Zhang, F. Bredin, M. Tremelling, J. C. Lee, C. Berzuini, and M. Parkes. 2011. Genetic association between NLRP3 variants and Crohn's disease does not replicate in a large UK panel. Inflamm. Bowel Dis. 17: 1387-1391.
30. Tsai, P. Y., S. M. Ka, J. M. Chang, H. C. Chen, H. A. Shui, C. Y. Li, K. F. Hua, W. L. Chang, J. J. Huang, S. S. Yang, and A. Chen. 2011. Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic. Biol. Med. 51: 744-754.
31. Zhao, J., H. Zhang, Y. Huang, H. Wang, S. Wang, C. Zhao, Y. Liang, and N. Yang. 2013. Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-kB activation. Int. Immunopharmacol. 17: 116-122.
32. Herman, S., A. Kny, C. Schorn, J. Pfatschbacher, B. Niederreiter, M. Herrmann, R. Holmdahl, G. Steiner, and M. H. Hoffmann. 2012. Cell death and cytokine production induced by autoimmunogenic hydrocarbon oils. Autoimmunity 45: 602-611.
33. Kahlenberg, J. M., S. Yalavarthi, W. Zhao, J. B. Hodgin, T. J. Reed, N. M. Tsuji, and M. J. Kaplan. 2014. An essential role of caspase 1 in the induction of murine lupus and its associated vascular damage. Arthritis Rheum. (Munch) 66: 152-162.
34. Lech, M., G. Lorenz, O. P. Kulkarni, M. O. Grosser, N. Stigrot, M. N. Darisipudi, R. Günthner, M. W. Wintergerst, D. Anz, H. E. Susanti, and H. J. Anders. 2014. NLRP3 and ASC suppress lupus-like autoimmunity by driving the immunosuppressive effects of TGF-b receptor signalling. Ann. Rheum. Dis. 10.1136/ annrheumdis-2014-205496.
35. Santiago-Raber, M. L., R. Baccala, K. M. Haraldsson, D. Choubey, T. A. Stewart, D. H. Kono, and A. N. Theofilopoulos. 2003. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197: 777-788.
36. Scatizzi, J. C., M. K. Haraldsson, K. M. Pollard, A. N. Theofilopoulos, and D. H. Kono. 2012. The Lbw2 locus promotes autoimmune hemolytic anemia. J. Immunol. 188: 3307-3314.
37. Morel, L. 2010. Genetics of SLE: evidence from mouse models. Nat Rev Rheumatol 6: 348-357.
38. Kono, D. H., and A. N. Theofilopoulos. 2006. Genetics of autoantibody production in mouse models of lupus. In Autoantibodies and Autoimmunity: Molecular Mechanisms. K. M. Pollard, ed. WILEY-VCH Verlag GmbH & Co., Weinheim, p. 543-562.
39. Theofilopoulos, A. N. 1992. Murine models of systemic lupus erythematosus. In Systemic Lupus Erythematosus. R. G. Lahita, ed. Churchill Livingstone, New York, p. 121-194.
40. Perry, D., A. Sang, Y. Yin, Y. Y. Zheng, and L. Morel. 2011. Murine models of systemic lupus erythematosus. J. Biomed. Biotechnol. 2011: 271694.
41. Roberts, T. L., A. Idris, J. A. Dunn, G. M. Kelly, C. M. Burnton, S. Hodgson, L. L. Hardy, V. Garceau, M. J. Sweet, I. L. Ross, et al. 2009. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 323: 1057-1060.
42. Yin, Q., D. P. Sester, Y. Tian, Y. S. Hsiao, A. Lu, J. A. Cridland, V. Sagulenko, S. J. Thygesen, D. Choubey, V. Hornung, et al. 2013. Molecular mechanism for p202-mediated specific inhibition of AIM2 inflammasome activation. Cell Reports 4: 327-339.
43. Rozzo, S. J., J. D. Allard, D. Choubey, T. J. Vyse, S. Izui, G. Peltz, and B. L. Kotzin. 2001. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 15: 435-443.
44. Stacey, K. J., G. R. Young, F. Clark, D. P. Sester, T. L. Roberts, S. Naik, M. J. Sweet, and D. A. Hume. 2003. The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J. Immunol. 170: 3614-3620.
45. Mariathasan, S., K. Newton, D. M. Monack, D. Vucic, D. M. French, W. P. Lee, M. Roose-Girma, S. Erickson, and V. M. Dixit. 2004. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430: 213-218.
46. Kuida, K., J. A. Lippke, G. Ku, M. W. Harding, D. J. Livingston, M. S. Su, and R. A. Flavell. 1995. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267: 2000-2003.
47. Martinon, F., V. Pétrilli, A. Mayor, A. Tardivel, and J. Tschopp. 2006. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237-241.
48. Andoniou, C. E., D. M. Andrews, M. Manzur, P. Ricciardi-Castagnoli, and M. A. Degli-Esposti. 2004. A novel checkpoint in the Bcl-2-regulated apoptotic pathway revealed by murine cytomegalovirus infection of dendritic cells. J. Cell Biol. 166: 827-837.
49. Haneklaus, M., M. Gerlic, M. Kurowska-Stolarska, A. A. Rainey, D. Pich, I. B. McInnes, W. Hammerschmidt, L. A. O'Neill, and S. L. Masters. 2012. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1b production. J. Immunol. 189: 3795-3799.
50. Jones, J. W., N. Kayagaki, P. Broz, T. Henry, K. Newton, K. O'Rourke, S. Chan, J. Dong, Y. Qu, M. Roose-Girma, et al. 2010. Absent in melanoma 2 is required for innate immune recognition of Francisella tularensis. Proc. Natl. Acad. Sci. USA 107: 9771-9776.
51. Hise, A. G., J. Tomalka, S. Ganesan, K. Patel, B. A. Hall, G. D. Brown, and K. A. Fitzgerald. 2009. An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. Cell Host Microbe 5: 487-497.
52. Bauernfeind, F. G., G. Horvath, A. Stutz, E. S. Alnemri, K. MacDonald, D. Speert, T. Fernandes-Alnemri, J. Wu, B. G. Monks, K. A. Fitzgerald, et al. 2009. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183: 787-791.
53. Bauernfeind, F., A. Rieger, F. A. Schildberg, P. A. Knolle, J. L. Schmid-Burgk, and V. Hornung. 2012. NLRP3 inflammasome activity is negatively controlled by miR-223. J. Immunol. 189: 4175-4181.
54. Popp, M. W., and L. E. Maquat. 2013. Organizing principles of mammalian nonsense-mediated mRNA decay. Annu. Rev. Genet. 47: 139-165.
55. Rodriguez, M. R., A. Lundgren, P. Sabastian, Q. Li, G. Churchill, and M. G. Brown. 2009. A Cmv2 QTL on chromosome X affects MCMV resistance in New Zealand male mice. Mamm. Genome 20: 414-423.
56. Corbel, M. J., and S. M. Eades. 1976. The relative susceptibility of New Zealand black and CBA mice to infection with opportunistic fungal pathogens. Sabouraudia 14: 17-32.
57. Wang, W., X. Wang, J. Chun, A. Vilaysane, S. Clark, G. French, N. A. Bracey, K. Trpkov, S. Bonni, H. J. Duff, et al. 2013. Inflammasome-independent NLRP3 augments TGF-b signaling in kidney epithelium. J. Immunol. 190: 1239-1249.
58. Miao, E. A., I. A. Leaf, P. M. Treuting, D. P. Mao, M. Dors, A. Sarkar, S. E. Warren, M. D. Wewers, and A. Aderem. 2010. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat. Immunol. 11: 1136-1142.
59. Elinav, E., T. Strowig, A. L. Kau, J. Henao-Mejia, C. A. Thaiss, C. J. Booth, D. R. Peaper, J. Bertin, S. C. Eisenbarth, J. I. Gordon, and R. A. Flavell. 2011. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145: 745-757.
60. East, J., and M. Branca. 1969. Autoimmune reactions and malignant changes in germ-free New Zealand Black mice. Clin. Exp. Immunol. 4: 621-635.
61. Leemans, J. C., L. Kors, H. J. Anders, and S. Florquin. 2014. Pattern recognition receptors and the inflammasome in kidney disease. Nat. Rev. Nephrol. 10: 398-414.
62. Guarda, G., M. Braun, F. Staehli, A. Tardivel, C. Mattmann, I. Fö rster, M. Farlik, T. Decker, R. A. Du Pasquier, P. Romero, and J. Tschopp. 2011. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34: 213-223.
63. Choubey, D., and R. Panchanathan. 2008. Interferon-inducible Ifi200-family genes in systemic lupus erythematosus. Immunol. Lett. 119: 32-41.
64. Haywood, M. E., S. J. Rose, S. Horswell, M. J. Lees, G. Fu, M. J. Walport, and B. J. Morley. 2006. Overlapping BXSB congenic intervals, in combination with microarray gene expression, reveal novel lupus candidate genes. Genes Immun. 7: 250-263.
65. Jørgensen, T. N., J. Alfaro, H. L. Enriquez, C. Jiang, W. M. Loo, S. Atencio, M. R. Bupp, C. M. Mailloux, T. Metzger, S. Flannery, et al. 2010. Development of murine lupus involves the combined genetic contribution of the SLAM and FcgammaR intervals within the Nba2 autoimmune susceptibility locus. J. Immunol. 184: 775-786.
66. Kono, D. H., R. W. Burlingame, D. G. Owens, A. Kuramochi, R. S. Balderas, D. Balomenos, and A. N. Theofilopoulos. 1994. Lupus susceptibility loci in New Zealand mice. Proc. Natl. Acad. Sci. USA 91: 10168-10172.
67. Kahlenberg, J. M., C. Carmona-Rivera, C. K. Smith, and M. J. Kaplan. 2013. Neutrophil extracellular trap-Associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J. Immunol. 190: 1217-1226.
68. Portales-Cervantes, L., P. Niño-Moreno, L. Doníz-Padilla, L. Baranda-Candido, M. García-Hernández, M. Salgado-Bustamante, R. González-Amaro, and D. Portales-Pérez. 2010. Expression and function of the P2X(7) purinergic receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. Hum. Immunol. 71: 818-825.
69. Portales-Cervantes, L., P. Niño-Moreno, M. Salgado-Bustamante, M. H. García-Hernández, L. Baranda-Candido, E. Reynaga-Hernández, C. Barajas-López, R. González-Amaro, and D. P. Portales-Pérez. 2012. The His155Tyr (489C.T) single nucleotide polymorphism of P2RX7 gene confers an enhanced function of P2X7 receptor in immune cells from patients with rheumatoid arthritis. Cell. Immunol. 276: 168-175.
70. Jacob, C. O., M. Eisenstein, M. C. Dinauer, W. Ming, Q. Liu, S. John, F. P. Quismorio, Jr., A. Reiff, B. L. Myones, K. M. Kaufman, et al. 2012. Lupusassociated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase. Proc. Natl. Acad. Sci. USA 109: E59-E67.